Please note: This website includes an accessibility system. Press Control-F11 to adjust the website to the visually impaired who are using a screen reader; Press Control-F10 to open an accessibility menu.

CTech 24/7

Enlivex

4 stories about Enlivex

Jerusalem-based Enlivex reports promising results in treating small number of Covid-19 patients
01.10.20|ReutersFive patients in severe or critical condition make full recoveries in under 10 days after receiving drug as part of clinical trial
Enlivex Leveraged Coronavirus to Get Money out of Shareholders
26.02.20|Uri Tal-Tene The company announced on Monday a plan to increase the manufacturing capacity for its experimental drug “in preparation for potential requests for treatment of coronavirus patients” and used the resulting stock boost to raise a direct offering of $8 million
CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down
02.10.19|Tzally GreenbergEnlivex develops cell-based treatments for life-threatening immune and inflammatory conditions, such as graft versus host disease, a post bone marrow transplant complication
Cell Immunotherapy Company Enlivex Merges With Nasdaq-Listed Bioblast, Raises $5.3 Million
28.03.19|Lilach BaumerThe merged entity listed on Nasdaq under the ticker “ENLV”

Twitter

Facebook

Rss

About CTech Terms of Use Privacy Policy

CTech 24/7

Enlivex

Jerusalem-based Enlivex reports promising results in treating small number of Covid-19 patients

Enlivex Leveraged Coronavirus to Get Money out of Shareholders

CEO of Nasdaq-Listed Cell Immunotherapy Company Enlivex Steps Down

Cell Immunotherapy Company Enlivex Merges With Nasdaq-Listed Bioblast, Raises $5.3 Million